BACKGROUND: National UK data on colorectal cancer (CRC) stage at diagnosis is incomplete. Site-specific fast-track (2-week wait) cancer data are not collected directly by NHS England. Policy making based on these data alone can lead to inaccuracy. AIMS: To review available data on key outcomes (cancer conversion rate and stage at diagnosis) for the UK's lower gastrointestinal 2-week wait pathway. METHODS: A comprehensive literature search was conducted between 2000 and 2017. Primary outcomes were cancer conversion rate and cancer stage at diagnosis. Results were expressed as proportions with 95% CIs. A random effects model was used for meta-analysis; heterogeneity was assessed by I2 . RESULTS: Of 95 papers reviewed, 49 were included in analysis with a total study population of 93,655. Cancer conversion rate was 7.7% (95% CI: 6.9-8.5). The proportion presenting at Dukes A = 11.2% (95% CI 7.4-15.6), B = 36.7% (95% CI 30.8-42.8), C = 35.7% (95% CI: 30.8-40.8) and D = 11.1% (95% CI 7.3-15.5). No colonic pathology was diagnosed in 54.6% (95% CI: 46.2-62.8). CONCLUSIONS: Only 7.7% of patients referred by the 2-week wait pathway were found to have CRC. No beneficial effect on stage at diagnosis was found compared to non-2-week wait referral pathways. Over half of patients had no colonic pathology and detection of adenomas was very low. These results should prompt a reconsideration of the benefits of the 2-week wait pathway in CRC diagnosis and outcomes, with more focus on strategies to improve patient selection.
BACKGROUND: National UK data on colorectal cancer (CRC) stage at diagnosis is incomplete. Site-specific fast-track (2-week wait) cancer data are not collected directly by NHS England. Policy making based on these data alone can lead to inaccuracy. AIMS: To review available data on key outcomes (cancer conversion rate and stage at diagnosis) for the UK's lower gastrointestinal 2-week wait pathway. METHODS: A comprehensive literature search was conducted between 2000 and 2017. Primary outcomes were cancer conversion rate and cancer stage at diagnosis. Results were expressed as proportions with 95% CIs. A random effects model was used for meta-analysis; heterogeneity was assessed by I2 . RESULTS: Of 95 papers reviewed, 49 were included in analysis with a total study population of 93,655. Cancer conversion rate was 7.7% (95% CI: 6.9-8.5). The proportion presenting at Dukes A = 11.2% (95% CI 7.4-15.6), B = 36.7% (95% CI 30.8-42.8), C = 35.7% (95% CI: 30.8-40.8) and D = 11.1% (95% CI 7.3-15.5). No colonic pathology was diagnosed in 54.6% (95% CI: 46.2-62.8). CONCLUSIONS: Only 7.7% of patients referred by the 2-week wait pathway were found to have CRC. No beneficial effect on stage at diagnosis was found compared to non-2-week wait referral pathways. Over half of patients had no colonic pathology and detection of adenomas was very low. These results should prompt a reconsideration of the benefits of the 2-week wait pathway in CRC diagnosis and outcomes, with more focus on strategies to improve patient selection.
Authors: Sofia M McCulloch; Imran Aziz; Annikka V Polster; Andreas-Bernd Pischel; Henrik Stålsmeden; Morteza Shafazand; Mattias Block; Gunnar Byröd; Björn Lindkvist; Hans Törnblom; Börje Jonefjäll; Magnus Simren Journal: United European Gastroenterol J Date: 2019-11-06 Impact factor: 4.623
Authors: Natalia Calanzani; Aina Chang; Marije Van Melle; Merel M Pannebakker; Garth Funston; Fiona M Walter Journal: Adv Ther Date: 2021-04-17 Impact factor: 3.845
Authors: Natalie Hunt; Christopher Rao; Robert Logan; Vishnu Chandrabalan; Jane Oakey; Claire Ainsworth; Neil Smith; Saswata Banerjee; Martin Myers Journal: BMJ Open Date: 2022-04-13 Impact factor: 3.006
Authors: Matthew Castelo; Colin Sue-Chue-Lam; Lawrence Paszat; Teruko Kishibe; Adena S Scheer; Bettina E Hansen; Nancy N Baxter Journal: PLoS One Date: 2022-09-12 Impact factor: 3.752
Authors: James L Turvill; Daniel Turnock; Dan Cottingham; Monica Haritakis; Laura Jeffery; Annabelle Girdwood; Tom Hearfield; Alex Mitchell; Ada Keding Journal: Br J Gen Pract Date: 2021-07-29 Impact factor: 6.302